69
Participants
Start Date
August 23, 2022
Primary Completion Date
August 26, 2024
Study Completion Date
August 31, 2028
ADVM-022
A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
ADVM-022
A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
Adverum Clinical Site 152, Morgantown
Adverum Clinical Site 122, West Columbia
Adverum Clinical Site 168, Jacksonville
Adverum Clinical Site 124, Deerfield Beach
Adverum Clinical Site 176, Fort Lauderdale
Adverum Clinical Site 101, Nashville
Adverum Clinical Site 163, Southaven
Adverum Clinical Site 502, Nantes
Adverum Clinical Site 161, Royal Oak
Adverum Clinical Site 167, Detroit
Adverum Clinical Site 144, Rapid City
Adverum Clinical Site 177, Omaha
Adverum Clinical Site 501, Lyon
Adverum Clinical Site 107, The Woodlands
Adverum Clinical Site 108, Bellaire
Adverum Clinical Site 151, San Antonio
Adverum Clinical Site 162, McAllen
Adverum Clinical Site 154, Austin
Adverum Clinical Site 123, Abilene
Adverum Clinical Site 116, Lakewood
Adverum Clinical Site 178, Phoenix
Adverum Clinical Site 126, Phoenix
Adverum Clinical Site 159, Tucson
Adverum Clinical Site 119, Reno
Adverum Clinical Site 100, Beverly Hills
Adverum Clinical Site 170, Pasadena
Adverum Clinical Site 172, Encino
Adverum Clinical Site 174, Poway
Adverum Clinical Site 164, Riverside
Adverum Clinical Site 169, Fullerton
Adverum Clinical Site 175, Santa Barbara
Adverum Clinical Site 500, Créteil
Adverum Clinical Site 166, Sacramento
Adverum Clinical Site 149, ‘Aiea
Adverum Clinical Site 165, Waterford
Adverum Clinical Site 146, Cherry Hill
Adverum Clinical Site 171, Teaneck
Adverum Clinical Site 600, London
Adverum Clinical Site 601, Oxford
Lead Sponsor
Adverum Biotechnologies, Inc.
INDUSTRY